Human Immunodeficiency VirusMAMASNCT03090802
MAMAS: Mentoring Adolescent Mothers at School
A study testing Mentoring Adolescent Mothers at School (MAMAS) in people with Human Immunodeficiency Virus and Herpes Simplex Type II, run by Drexel University at 1 site in South Africa.
Trial summary
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school. Read more about this study
- Who is it for?
- Ages 14 to 19 years, women only
- Conditions the study is for
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia
- What is being tested?
- Mentoring Adolescent Mothers at School (MAMAS)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 152 participants
- Where
- 1 siteSouth Africa
- Study dates
- 26 Jun 2017to 30 Nov 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 19 years
- Women only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Given birth in the last two weeks
- 14-19 years of age
- Have been enrolled in school in Umlazi in the previous year
- Planning to stay in the residential area for the next 9 months
- Parent/guardian is willing and available to consent
Who cannot join
- Not currently co-enrolled in other research programs
- Not interested in participating in the program
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Re-enrolling Young South African Mothers in School as a Social Vaccine Against HIV Transmission
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school. The objective of the intervention is to have older mentor mothers, who themselves were pregnant adolescents, to mentor younger adolescent mothers. Mentor mothers will provide ongoing psychosocial support, help navigate re-admission to school, and help facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period. Our combination social protection program will enhance resilience of young adolescent mothers to facilitate their return to school and thereby reduce HIV risk. The investigators will evaluate the efficacy of the intervention using a pre-test post-test randomized controlled trial design. Participants in the intervention will receive the Mentoring Adolescent Mothers At School (MAMAS) intervention and standard postpartum care. Those in the control arm will receive standard postpartum care. Additionally, for those participants randomized to the intervention arm, mentor mothers will use participatory visual methods (e.g., photovoice, cell-films, drawings) as part of the intervention itself. Last, among those participants randomized to the intervention arm and who return for their 9-month assessment, the investigators will conduct 20 in-depth interviews to understand the process of resilience development from their perspective.
Primary outcomes:
Read more
School outcomes (initial outcomes) HYP 1.1: Program participation will increase school enrollment HYP 1.2: Program participation will increase school engagement
HIV risk outcomes (intermediate outcomes) HYP 2.1: Program participation will reduce number of sexual partners HYP 2.2: Program participation will reduce inconsistent condom use HYP 2.3: Program participation will reduce intimate partner violence HYP 2.4: Program participation will decrease HIV/STI infection HYP 2.5 (for HIV+): Program participation will increase retention in care
Secondary outcomes:
HYP 5: Program participation will increase peer support HYP 6: Program participation will increase familial support HYP 7: Program participation will increase school re-admission HYP 8: Program participation will increase application to the child support grant HYP 9: Program participation will increase receipt of the child support grant
Read the detailed description
All study activities will take place in Umlazi township in eThekwini district. The township is served by one regional hospital, Prince Mshiyeni Memorial Hospital, which is the referral hospital for 17 primary health care clinics.
Participants will be involved in the study from delivery to 9 months postpartum. The intervention study will be delivered in two cohorts (n=240 per cohort). The first cohort will be enrolled beginning in May 2017. The investigators anticipate that 4 adolescent mothers will be enrolled per day based on the monthly number of adolescent deliveries at Prince Mshiyieni hospital and our own capacity. Therefore, investigators will be finished enrolling the first cohort by July 2017. The first cohort will complete the end line assessment between December 2017-February 2018.
The investigators will begin enrolling the second cohort in September 2017 and will complete enrollment by November 2017. The second cohort will complete the end line assessment between June-August, 2018. Primary outcome analysis will be complete by October, 2018.
MAMAS Intervention The investigators will roll out the program with two cohorts of adolescent mothers (n=240 per cohort); each mentor mother will work with 10 adolescent mothers per cohort. Within each cohort, there will be an intervention arm and control arm (N=240 per arm for the both cohorts). The participants of the program arm will have 15 group sessions with mentor and up to 2 home visits from 3 weeks-6 months postpartum. Investigators will use participatory visual methods (e.g., photovoice, journaling, and drawing) throughout program implementation with adolescent mothers to understand and further facilitate their process of resilience development. As one example, as part of the mentoring process, adolescent mothers may be asked to engage in reflexive journaling. Mentor mothers will ask adolescent mothers who are comfortable doing so to share excerpts from their journals in a particular group session. Through the group session, the adolescent mothers themselves will identify common barriers they are facing and will work together to overcome them. Mentor mothers will keep weekly logs documenting what was covered in the sessions; these will be abstracted as part of ongoing monitoring and evaluation.
All 480 participants will complete a baseline behavioral and biological assessment (HIV and HSV-2 testing) at 2 weeks postpartum and an additional baseline biological assessment (Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia trachomatis testing) at 6 weeks postpartum. Further, all participants will receive regular postpartum and well-baby visits at 6 weeks, 10 weeks, 14 weeks and 6 months with an adolescent-friendly study nurse. During the visits, participants will complete routine assessments. At 9-months postpartum, participants will complete end line behavioral and biological assessment (HIV, HSV-2 Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia trachomatis testing).
Provision to Privacy All participants will receive adolescent-friendly clinical services with our study nurse during the postnatal period. The study nurse will provide standard of care clinical services, and will have gone through training to ensure she is providing youth-friendly care. In addition, a trained research assistant will administer all behavioral assessments and be available for any queries that participants have as they complete the survey. The research assistant will complete training on multicultural sensitivity, gender-based violence, and ethical guidelines as recommended by the WHO Violence Against Women (VAW) study to engage with participants in a supportive and non-judgmental manner, deal with sensitive issues, and respond to distressed participants.
Additionally, the following systems are in place to maintain cohort retention and follow up while protecting the privacy interests of subjects: At enrollment, study participants will be asked if they are willing to share their telephone number, their physical home address and a postal address. Women will be told that providing this information is entirely voluntary, and will only be used to follow up with the women to remind them of their appointments. Study participants in the intervention trial will be contacted by text message prior to a study visit to remind them of their visit. Study participants who miss their scheduled appointment are contacted within 24 hours. The first line of contact is an SMS. The second is a reminder telephone call to the participant directly or to a close contact that is identified by the client, while maintaining confidentiality. If the study staff cannot reach the participant, she will call once per day over the next three days. If the tracer still cannot reach the participant by the end of the third day, the tracer will do a home visit if home location was provided by the participant. Home visits are done by tracers familiar with the residential areas. For the proposed study, the investigators will employ two full-time tracers. If the participant has changed her address maximum information is gathered (while maintaining confidentiality of the participant) from neighbors and relatives that form the basis of further contact. A participant will be considered lost to follow-up after 3 unsuccessful attempts of phone contact and 2 unsuccessful home visits. A SMS and phone script that will be used to contact women and remind them of their appointments.
A similar system for tracing study participants was used in the previous clinical trials implemented and has resulted in retention rates of higher than 75%, with no adverse events associated with tracing reported.
Data Management and Analysis Data will be primarily managed on-site by a data entry and management team. All risks will be minimized through staff ethics training, layered data security and by restricting access of sensitive information to staff members who have a specific need for the information. Furthermore, as part of the training that investigators conduct for all staff members, investigators will include a training module on the confidential nature of the data. Investigators have conducted similar training modules for research staff in other studies. Following the training, all staff will sign an Oath of Confidentiality.
Data Security for all Data All participants will be assigned a participant identifier (PID) after randomization. Thereafter, all biological and non-biological samples/data will only be identifiable vis-a-vis the PID. Participant's names will never appear on the samples/data. Further, consent forms and any other forms with personal identifiers will be kept separate from data files in key-locked filing cabinets. A computerized follow-up system which links identification numbers and personal information will be kept on a computer with password protection. Only the site PI, Dr. Daya Moodley and authorized study staff who have completed all required ethics training will have access to the computer. Protection against loss of data is provided through scheduled backup of data files.
Non-biological Data Data will be collected using Samsung Galaxy or equivalent Tablets running customized version of Android operating system. The investigators have multiple levels of security measures to ensure the safety of data on the tablets. With the customized version of operating system, the interviewers are allowed access to only certain apps and settings on the tablets. A password is required to activate the tablet and a second password must be entered to access the data capture software. There are also separate levels of access for interviewers, field supervisors, and system administrators. Only users with administrator level access will can delete data that had been previously captured. Further, the data captured on the device will be in a machine-readable (xml) format and is not easy to interpret without using a computer program. To add another layer of security, once the data has been transferred to the project server, it will be removed from the device. As an additional security measure, lost or stolen tablets can be tracked and have their data erased remotely by the data team when the lost or stolen tablet is connected to a Wi-Fi or cellular network.
All data captured by the tablets will be transmitted to the project server using HTTPS, which is a widely-used communications protocol for secure communication over a computer network. HTTPS provides authentication of the web app and associated web server that one is communicating with, which protects against malicious attacks. Additionally, it provides bidirectional encryption of communications between a client and server, which protects against eavesdropping and tampering with and/or forging the contents of the communication.
Once the data is on project server, it allows real time monitoring of progress in the field, reported via automated Benchmark reporting tables on a password protected website, and facilitates monitoring of the status of data collection, and helps make rapid corrections to assure timely adherence to the timeline. In addition, the data will be processed to create incremental Stata datasets every week and will be sent through email in an encrypted format to Project coordinator, who in turn will run weekly QC activities and return any queries to field staff.
Data Collection, Storage and Sharing for Biological Data Biological specimens will be stored at the CAPRISA repository in -70 refrigerators. The samples will be stored in temperature controlled and monitored environment. Specimens will be stored until all assays are complete which is dependent on the receipt of funds for the relevant assays proposed. Repository staff who maintain the samples daily will have access to the samples.
Statistical Analysis The investigators will use appropriate bivariate and multivariate analysis to test whether adolescent mothers who received the intervention have lower levels of STIs and HIV risk than those in the control arm. Multivariate analysis will be used to measure the association between treatment arm and school reenrollment. For HIV-positive participants, investigators will assess whether receiving the intervention increases retention in care. Analyses will be completed using SAS statistical programs.
Power Analysis Investigators used data from a previous trial in the same setting to help estimate the appropriate sample size for our RCT [1]. Specifically, in the previous study, investigators had a 26.5% prevalence of consistent condom use and a 21.6% prevalence of any STI in the control group at the postpartum assessment.
Outcome 1: STI. Investigators estimate that the total sample size needed at follow-up to detect a standardized effect (d) of .20 (OR=.69) of our intervention on STI with 80% power (2-sided, alpha=.05) is 350 (total across both arms). The investigators inflated this sample size assuming an attrition rate from baseline to follow-up of 25% (350/.70=467).
Outcome 2: Inconsistent condom use. The investigators estimate that the total sample size needed at follow-up to detect a standardized effect (d) of .20 (OR=.69) of our intervention on inconsistent condom use with 80% power (2-sided, alpha=.05) is 314 (total across both arms). Investigators inflated this sample size assuming an attrition rate from baseline to follow-up of 25% (314/.70=419).
While investigators estimated that 467 participants would provide sufficient power to detect an effect on STI outcomes, investigators increased our sample size to 480 participants so that each of the 12 mentor mothers would be delivering the intervention to an equal number of participants (n=10) in each cohort.
- Conditions
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia, Gonorrhea, Trichomonas Vaginitis
- Being tested
- Mentoring Adolescent Mothers at School (MAMAS)
- Keywords
- Human Immunodeficiency Virus, resilience, adolescent mothers, Sub-Saharan Africa, intimate partner violence, postpartum period
- Medical subject headings
- Acquired Immunodeficiency Syndrome, Chlamydia Infections, Gonorrhea, Trichomonas Vaginitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mentoring Adolescent Mothers at School (MAMAS)Behavioural
Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum. Receives: Behavioral: Mentoring Adolescent Mothers at School (MAMAS) |
| Control | No intervention | Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-reported enrollment into school
Binary outcome
Measured: 9-months postpartum
Self-report missed days in school in the past 30 days
Categorical outcome (5)
Measured: 9-months postpartum
Self-reported number of men a participant has had sex with in the past 30 days
Measured: 9-months postpartum
Self-reported percentage of condom use while having sex in the past 30 days
Categorical outcome (6)
Measured: 9-months postpartum
IPV in the last 30 days (WHO modified conflict tactic scale)
Consist of 10-items.
Measured: 9-months postpartum
Results from HIV rapid test
Binary outcome
Measured: 9-months postpartum
Results from Gonorrhea test using BD ProbeTec ET Amplified DNA Assay
Binary outcome
Measured: 9-months postpartum
Results from Chlamydia test using BD ProbeTec ET Amplified DNA Assay
Binary outcome
Measured: 9-months postpartum
Results from Trichomonas vaginalis test using in-house PCR
Binary outcome
Measured: 9-months postpartum
Secondary outcomes (4)
Score on peer support scale (self-reported)
Consist of 7 items. Each item scored on 4 point scale.
Measured: 9-months postpartum
Score on familial support scale (self-reported)
Consist of 7 items. Each item scored on 4 point scale.
Measured: 9-months postpartum
Whether participant applied for child support grant (self-reported)
Binary outcome
Measured: 9-months postpartum
Whether participant received the child support grant (self-reported)
Binary outcome
Measured: 9-months postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2017
- Study start26 Jun 2017
- Primary completion30 Nov 2018
- Study completion30 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Human Immunodeficiency VirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 152 participants (actual)
Sponsor and investigators
- Lead sponsor
- Drexel University
- Sponsor type
- University, hospital or other
- Collaborators
- University of KwaZulu, University of North Carolina, Chapel Hill
- Responsible party
- Sponsor
- Investigators
- Allison K Groves, PhD, MHS, Principal investigator, Drexel University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03090802
- Sponsor's protocol ID
- 1612005048
- Other IDs
- S-LMAQM-16-CA-1103
- Acronym
- MAMAS
- Status last verified
- Sep 2021
- First submitted
- 16 Mar 2017
- Last updated
- 24 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Persons requesting permission to access non-biological data (behavioral assessments) will communicate with the project PI, Dr. Ali Groves, who will provide/decline permission. Persons requesting permission to access biological data (biological assessments and specimens) will communicate with the site PI, Dr. Daya Moodley, who will provide/decline permission. If permission is granted, the relevant research staff will be alerted to the release of samples/data as requested. A list of the participant samples/data being released will be provided to the PI, and the person requesting the data. Both will acknowledge release and receipt of samples/data. Data that will be provided with the samples will be limited to demographic data, no personal participant information will be provided; only participant identifiers will be used to identify the specific sample/data requested.
Publications
Maman S, Moodley D, McNaughton-Reyes HL, Groves AK, Kagee A, Moodley P. Efficacy of enhanced HIV counseling for risk reduction during pregnancy and in the postpartum period: a randomized controlled trial. PLoS One. 2014 May 13;9(5):e97092. doi: 10.1371/journal.pone.0097092. eCollection 2014.
PubMed 24824050
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Re-enrolling Young South African Mothers in School as a Social Vaccine Against HIV Transmission
- ClinicalTrials.gov ID
- NCT03090802
- Acronym / sponsor ID
- MAMAS / 1612005048
- Conditions
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia, Gonorrhea, Trichomonas Vaginitis
- Keywords
- Human Immunodeficiency Virus, resilience, adolescent mothers, Sub-Saharan Africa, intimate partner violence, postpartum period
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 152 participants (actual)
- Lead sponsor
- Drexel UniversityUniversity, hospital or other
- Collaborators
- University of KwaZulu, University of North Carolina, Chapel Hill
- Study start
- 26 Jun 2017 (actual)
- Primary completion
- 30 Nov 2018 (actual)
- Study completion
- 30 Nov 2018 (actual)
- First posted
- 27 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school. The objective of the intervention is to have older mentor mothers, who themselves were pregnant adolescents, to mentor younger adolescent mothers. Mentor mothers will provide ongoing psychosocial support, help navigate re-admission to school, and help facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period. Our combination social protection program will enhance resilience of young adolescent mothers to facilitate their return to school and thereby reduce HIV risk. The investigators will evaluate the efficacy of the intervention using a pre-test post-test randomized controlled trial design. Participants in the intervention will receive the Mentoring Adolescent Mothers At School (MAMAS) intervention and standard postpartum care. Those in the control arm will receive standard postpartum care. Additionally, for those participants randomized to the intervention arm, mentor mothers will use participatory visual methods (e.g., photovoice, cell-films, drawings) as part of the intervention itself. Last, among those participants randomized to the intervention arm and who return for their 9-month assessment, the investigators will conduct 20 in-depth interviews to understand the process of resilience development from their perspective.
Primary outcomes:
School outcomes (initial outcomes) HYP 1.1: Program participation will increase school enrollment HYP 1.2: Program participation will increase school engagement
HIV risk outcomes (intermediate outcomes) HYP 2.1: Program participation will reduce number of sexual partners HYP 2.2: Program participation will reduce inconsistent condom use HYP 2.3: Program participation will reduce intimate partner violence HYP 2.4: Program participation will decrease HIV/STI infection HYP 2.5 (for HIV+): Program participation will increase retention in care
Secondary outcomes:
HYP 5: Program participation will increase peer support HYP 6: Program participation will increase familial support HYP 7: Program participation will increase school re-admission HYP 8: Program participation will increase application to the child support grant HYP 9: Program participation will increase receipt of the child support grant
Detailed description
All study activities will take place in Umlazi township in eThekwini district. The township is served by one regional hospital, Prince Mshiyeni Memorial Hospital, which is the referral hospital for 17 primary health care clinics.
Participants will be involved in the study from delivery to 9 months postpartum. The intervention study will be delivered in two cohorts (n=240 per cohort). The first cohort will be enrolled beginning in May 2017. The investigators anticipate that 4 adolescent mothers will be enrolled per day based on the monthly number of adolescent deliveries at Prince Mshiyieni hospital and our own capacity. Therefore, investigators will be finished enrolling the first cohort by July 2017. The first cohort will complete the end line assessment between December 2017-February 2018.
The investigators will begin enrolling the second cohort in September 2017 and will complete enrollment by November 2017. The second cohort will complete the end line assessment between June-August, 2018. Primary outcome analysis will be complete by October, 2018.
MAMAS Intervention The investigators will roll out the program with two cohorts of adolescent mothers (n=240 per cohort); each mentor mother will work with 10 adolescent mothers per cohort. Within each cohort, there will be an intervention arm and control arm (N=240 per arm for the both cohorts). The participants of the program arm will have 15 group sessions with mentor and up to 2 home visits from 3 weeks-6 months postpartum. Investigators will use participatory visual methods (e.g., photovoice, journaling, and drawing) throughout program implementation with adolescent mothers to understand and further facilitate their process of resilience development. As one example, as part of the mentoring process, adolescent mothers may be asked to engage in reflexive journaling. Mentor mothers will ask adolescent mothers who are comfortable doing so to share excerpts from their journals in a particular group session. Through the group session, the adolescent mothers themselves will identify common barriers they are facing and will work together to overcome them. Mentor mothers will keep weekly logs documenting what was covered in the sessions; these will be abstracted as part of ongoing monitoring and evaluation.
All 480 participants will complete a baseline behavioral and biological assessment (HIV and HSV-2 testing) at 2 weeks postpartum and an additional baseline biological assessment (Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia trachomatis testing) at 6 weeks postpartum. Further, all participants will receive regular postpartum and well-baby visits at 6 weeks, 10 weeks, 14 weeks and 6 months with an adolescent-friendly study nurse. During the visits, participants will complete routine assessments. At 9-months postpartum, participants will complete end line behavioral and biological assessment (HIV, HSV-2 Trichomonas vaginalis, Neisseria gonorrhea and Chlamydia trachomatis testing).
Provision to Privacy All participants will receive adolescent-friendly clinical services with our study nurse during the postnatal period. The study nurse will provide standard of care clinical services, and will have gone through training to ensure she is providing youth-friendly care. In addition, a trained research assistant will administer all behavioral assessments and be available for any queries that participants have as they complete the survey. The research assistant will complete training on multicultural sensitivity, gender-based violence, and ethical guidelines as recommended by the WHO Violence Against Women (VAW) study to engage with participants in a supportive and non-judgmental manner, deal with sensitive issues, and respond to distressed participants.
Additionally, the following systems are in place to maintain cohort retention and follow up while protecting the privacy interests of subjects: At enrollment, study participants will be asked if they are willing to share their telephone number, their physical home address and a postal address. Women will be told that providing this information is entirely voluntary, and will only be used to follow up with the women to remind them of their appointments. Study participants in the intervention trial will be contacted by text message prior to a study visit to remind them of their visit. Study participants who miss their scheduled appointment are contacted within 24 hours. The first line of contact is an SMS. The second is a reminder telephone call to the participant directly or to a close contact that is identified by the client, while maintaining confidentiality. If the study staff cannot reach the participant, she will call once per day over the next three days. If the tracer still cannot reach the participant by the end of the third day, the tracer will do a home visit if home location was provided by the participant. Home visits are done by tracers familiar with the residential areas. For the proposed study, the investigators will employ two full-time tracers. If the participant has changed her address maximum information is gathered (while maintaining confidentiality of the participant) from neighbors and relatives that form the basis of further contact. A participant will be considered lost to follow-up after 3 unsuccessful attempts of phone contact and 2 unsuccessful home visits. A SMS and phone script that will be used to contact women and remind them of their appointments.
A similar system for tracing study participants was used in the previous clinical trials implemented and has resulted in retention rates of higher than 75%, with no adverse events associated with tracing reported.
Data Management and Analysis Data will be primarily managed on-site by a data entry and management team. All risks will be minimized through staff ethics training, layered data security and by restricting access of sensitive information to staff members who have a specific need for the information. Furthermore, as part of the training that investigators conduct for all staff members, investigators will include a training module on the confidential nature of the data. Investigators have conducted similar training modules for research staff in other studies. Following the training, all staff will sign an Oath of Confidentiality.
Data Security for all Data All participants will be assigned a participant identifier (PID) after randomization. Thereafter, all biological and non-biological samples/data will only be identifiable vis-a-vis the PID. Participant's names will never appear on the samples/data. Further, consent forms and any other forms with personal identifiers will be kept separate from data files in key-locked filing cabinets. A computerized follow-up system which links identification numbers and personal information will be kept on a computer with password protection. Only the site PI, Dr. Daya Moodley and authorized study staff who have completed all required ethics training will have access to the computer. Protection against loss of data is provided through scheduled backup of data files.
Non-biological Data Data will be collected using Samsung Galaxy or equivalent Tablets running customized version of Android operating system. The investigators have multiple levels of security measures to ensure the safety of data on the tablets. With the customized version of operating system, the interviewers are allowed access to only certain apps and settings on the tablets. A password is required to activate the tablet and a second password must be entered to access the data capture software. There are also separate levels of access for interviewers, field supervisors, and system administrators. Only users with administrator level access will can delete data that had been previously captured. Further, the data captured on the device will be in a machine-readable (xml) format and is not easy to interpret without using a computer program. To add another layer of security, once the data has been transferred to the project server, it will be removed from the device. As an additional security measure, lost or stolen tablets can be tracked and have their data erased remotely by the data team when the lost or stolen tablet is connected to a Wi-Fi or cellular network.
All data captured by the tablets will be transmitted to the project server using HTTPS, which is a widely-used communications protocol for secure communication over a computer network. HTTPS provides authentication of the web app and associated web server that one is communicating with, which protects against malicious attacks. Additionally, it provides bidirectional encryption of communications between a client and server, which protects against eavesdropping and tampering with and/or forging the contents of the communication.
Once the data is on project server, it allows real time monitoring of progress in the field, reported via automated Benchmark reporting tables on a password protected website, and facilitates monitoring of the status of data collection, and helps make rapid corrections to assure timely adherence to the timeline. In addition, the data will be processed to create incremental Stata datasets every week and will be sent through email in an encrypted format to Project coordinator, who in turn will run weekly QC activities and return any queries to field staff.
Data Collection, Storage and Sharing for Biological Data Biological specimens will be stored at the CAPRISA repository in -70 refrigerators. The samples will be stored in temperature controlled and monitored environment. Specimens will be stored until all assays are complete which is dependent on the receipt of funds for the relevant assays proposed. Repository staff who maintain the samples daily will have access to the samples.
Statistical Analysis The investigators will use appropriate bivariate and multivariate analysis to test whether adolescent mothers who received the intervention have lower levels of STIs and HIV risk than those in the control arm. Multivariate analysis will be used to measure the association between treatment arm and school reenrollment. For HIV-positive participants, investigators will assess whether receiving the intervention increases retention in care. Analyses will be completed using SAS statistical programs.
Power Analysis Investigators used data from a previous trial in the same setting to help estimate the appropriate sample size for our RCT [1]. Specifically, in the previous study, investigators had a 26.5% prevalence of consistent condom use and a 21.6% prevalence of any STI in the control group at the postpartum assessment.
Outcome 1: STI. Investigators estimate that the total sample size needed at follow-up to detect a standardized effect (d) of .20 (OR=.69) of our intervention on STI with 80% power (2-sided, alpha=.05) is 350 (total across both arms). The investigators inflated this sample size assuming an attrition rate from baseline to follow-up of 25% (350/.70=467).
Outcome 2: Inconsistent condom use. The investigators estimate that the total sample size needed at follow-up to detect a standardized effect (d) of .20 (OR=.69) of our intervention on inconsistent condom use with 80% power (2-sided, alpha=.05) is 314 (total across both arms). Investigators inflated this sample size assuming an attrition rate from baseline to follow-up of 25% (314/.70=419).
While investigators estimated that 467 participants would provide sufficient power to detect an effect on STI outcomes, investigators increased our sample size to 480 participants so that each of the 12 mentor mothers would be delivering the intervention to an equal number of participants (n=10) in each cohort.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Mentoring Adolescent Mothers at School (MAMAS)The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum. |
| Control | No intervention | –Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum. |
Who may qualify
- Ages
- 14 to 19 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Given birth in the last two weeks
- 14-19 years of age
- Have been enrolled in school in Umlazi in the previous year
- Planning to stay in the residential area for the next 9 months
- Parent/guardian is willing and available to consent
Key exclusion criteria (2 listed)
- Not currently co-enrolled in other research programs
- Not interested in participating in the program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mentoring Adolescent Mothers at School (MAMAS)Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period. | Behavioural | Intervention |
Primary outcome
Self-reported enrollment into school
Time frame: 9-months postpartum
Binary outcome
Self-report missed days in school in the past 30 days
Time frame: 9-months postpartum
Categorical outcome (5)
Self-reported number of men a participant has had sex with in the past 30 days
Time frame: 9-months postpartum
Self-reported percentage of condom use while having sex in the past 30 days
Time frame: 9-months postpartum
Categorical outcome (6)
IPV in the last 30 days (WHO modified conflict tactic scale)
Time frame: 9-months postpartum
Consist of 10-items.
Results from HIV rapid test
Time frame: 9-months postpartum
Binary outcome
Results from Gonorrhea test using BD ProbeTec ET Amplified DNA Assay
Time frame: 9-months postpartum
Binary outcome
Results from Chlamydia test using BD ProbeTec ET Amplified DNA Assay
Time frame: 9-months postpartum
Binary outcome
Results from Trichomonas vaginalis test using in-house PCR
Time frame: 9-months postpartum
Binary outcome
4 secondary outcomes
Score on peer support scale (self-reported)
Time frame: 9-months postpartum
Score on familial support scale (self-reported)
Time frame: 9-months postpartum
Whether participant applied for child support grant (self-reported)
Time frame: 9-months postpartum
Whether participant received the child support grant (self-reported)
Time frame: 9-months postpartum
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2021.
- Background: PubMed 24824050Maman S, Moodley D, McNaughton-Reyes HL, Groves AK, Kagee A, Moodley P. Efficacy of enhanced HIV counseling for risk reduction during pregnancy and in the postpartum period: a randomized controlled trial. PLoS One. 2014 May 13;9(5):e97092. doi: 10.1371/journal.pone.0097092. eCollection 2014.
- Individual participant dataSharing planned: Yes. Persons requesting permission to access non-biological data (behavioral assessments) will communicate with the project PI, Dr. Ali Groves, who will provide/decline permission. Persons requesting permission to access biological data (biological assessments and specimens) will communicate with the site PI, Dr. Daya Moodley, who will provide/decline permission. If permission is granted, the relevant research staff will be alerted to the release of samples/data as requested. A list of the participant samples/data being released will be provided to the PI, and the person requesting the data. Both will acknowledge release and receipt of samples/data. Data that will be provided with the samples will be limited to demographic data, no personal participant information will be provided; only participant identifiers will be used to identify the specific sample/data requested.
Related trials for Human Immunodeficiency Virus
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Allison K Groves, PhD, MHS principal investigator
Drexel University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mentoring Adolescent Mothers at School (MAMAS) in people with Human Immunodeficiency Virus and Herpes Simplex Type II, run by Drexel University at 1 site in South Africa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-reported enrollment into school (time frame: 9-months postpartum). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03090802, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2021.